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LTHOUGH prolongation of renal allograft survival by
A
donor pretreatment with immunosuppressives in animal

The effect of donor pretreatment on perfused cadaver
kidney allografts was evaluated in 40 recipients at Henry
Ford Hospital over a two-year period. Ofthe 40,23 received
kidneys from donors pretreated with 40 mglK each of
cyclophosphamide and methylprednisolone during tbe first
year of the study and upto 70 mg/ K during the second year.
Our results indicated that donor pretreatment for five to
eight hours did not consistently improve survival rates in
pretreated perfused cadaver kidneys following transplantation. The use of cyclophosphamide for donor pretreatment
does not prevent the use of continuous perfusion to preserve
human kidneys. Dosages up to 70 mg/K may be used
without an apparent increase in acute tubular necrosis or
significant early loss of renal function.

studies has been well established,' these findings have not
been conclusive in humans. Guttmann and co-workers^
have reported improved graft survival following donor
pretreatment with a combination of cyclophosphamide (40
mg/K) and methylprednisolone (40 mg/K) five to eight
hours before harvesting. Zincke and Woods^ have reported
that cyclophosphamide (60 m g / K) six to eight hours before
harvesting followed in three to five hours by the same dose
of methylprednisolone was also effective. Initially, in our
M i c h i g a n study pretreatment w i t h 40 m g / K each of
cyclophosphamide and methylprednisolone before harvesting showed prolonged graft survival. However, when donors were completely randomized, this augmented graft
survival was no longer apparent.'' Chatterjee used 70 mg/ K
of methylprednisolone alone as pretreatment in a control led
double-blind study and found it to be ineffective in prolonging graft survival.' Jeffery et al in a randomized study used
cyclophosphamide (100 mg/K) and methylprednisolone
(70 mg/K) four hours before nephrectomy, but found no
beneficial effect on graft survival or function.'' The purpose
ofthis study is to eval uate the effect of donor pretreatment on
perfused cadaver kidney allografts at Henry Ford Hospital.

Patients and Methods
From June 1973 to July 1975, 23 recipients received kidneys
from pretreated donors and 17 from nonpretreated. During
the first year, donors were selected and pretreated five to
eight hours before nephrectomy with 40 m g / K each of
cyclophosphamide and methylprednisolone. Afterward, donors were alternated and finally randomized between
t r e a t e d a n d c o n t r o l g r o u p s . First t h e d o s a g e of
cyclophosphamide and then of methylprednisolone was
increased to 70 mg/K after the first year. These drugs were
given after brain death had been declared.
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Blood pressure ofthe donors was supported to 100 mm Hg
systolic wfth dopamine as necessary, and urine output was
maintained with adequate fluid replacement. All kidneys
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were preserved at 4°C by hypothermic pulsatile perfusion
with cryoprecipitated plasma for variable periods of time
(average of 14 hours). The surgical technique, immunosuppression, and postoperative treatment remained constant
throughout the study. A cooling jacket during transplantation was used to reduce rewarming time.'"' Azathioprine 5.0
mg/K was given for one day, then 2.0 m g / K / d a y for 14
days, and then 1.0-2.0 m g / K / d a y adjusted tothe level ofthe
white blood cell count. Methylprednisolone was given at a
dose of 1.2 m g / K / d a y on the day of surgery. Thereafter, the
total dose was reduced by 2.0 mg each day to a maintenance
dose of 10 to 30 mg daily. For rejection episodes, patients
were treated with 1.0 gm of intravenously administered
methylprednisolone for each of three consecutive days.

Diabetes, the number of previous transplants, and sex did
not significantly affect the survival rate ofthe grafts in either
the pretreated or nonpretreated groups. Graft failure due to
acute tubular necrosis (Figure 1) and infection occurred in
both treated and control groups equally.

Discussion
Overall, donor pretreatment for five to eight hours did not
consistently improve survival rates in pretreated perfused
cadaver kidneys following transplantation. These results
contrast wfth the findings of Guttmann et a/^ and Zincke,^
who have had excellent results with pretreated kidneys.
Three variables must be considered in comparing these
clinical studies: 1) method of preservation, 2) dosage and
timingof the pretreatment drugs, and 3) the degree to which
the kidney donor source has been randomized.

All patients have been at risk for at least six months. The life
table method of Merrell and Shulman' was used to determine the graft survival.

In Guttmann's series, continuous perfusion was not used.
The kidneys were cooled by flushing and by surface cooling
with cold Ringer's lactate. They were then transplanted with
a maximum of cold preservation time, generally two to six
hours.^ This routine is supported by studies showing that
canine kidneys on perfusion or in Collins solution will not
survive as viable grafts in the recipient if the donor is
pretreated with cyclophosphamide. Asa result ofthis "preservation intolerance" many programs dependent on perfusion have been discouraged from studying pretreatment.
However, both Zincke's study^ of the substantial number
of h u m a n k i d n e y s t h a t f u n c t i o n e d w e l l a f t e r
cyclophosphamide pretreatment (60 mg/K) and our work
with good function of 24-hour perfused, pretreated dog

Results
The actuarial functional survival rate of all recipients who
received grafts from all pretreated donors at one, two, and
three years was 48%, 35%, and 30%, respectively (Figure 1).
These figures do not significantly differ from those for
nonpretreated group, in which the survival rate atone, two,
and three years was 47%, 4 1 % , and 4 1 % , respectively
(Figure 1). Better survival was achieved in the first group in
which donors had been selected and treated with 40 mg/ K
of cyclophosphamide and methylprednisolone. The actuarial graft survival rates in this group were 63%, 50%, and
38% at one, two, and three years, respectively (Figure 2).
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Fig.1
Graft survival in months of kidneys w i t h and without acute tubular necrosis (ATN) Left: pretreated kidneys. Right: nonpretreated kidneys.
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kidneys. All of the kidneys in the Zincke's study were
preserved by continuous perfusion. The difference in oneyear graft survival between pretreated and nontreated
groups was more substantial than in Guttmann's series (82%
versus 43%).

(3;

(14)

(1)

In both ofthese studies, it is important to question the role of
donor selection on the results in the control group. Programs
analyzingtheir kidney procurement program often report an
increase in the survival of kidneys harvested locally. In the
Michigan study kidneys were harvested from all over the
state through its cooperative organ donor program, and an
effort was made to keep the number of treated and nontreated patients equal. It is true that pretreated kidneys came
from donors who were known to be stable and from
institutions that would transport blood or nodes for typing
before pretreatment started. However, the statistics of age
and length of perfusion did not differ between the pretreated and nonpretreated groups. The most significant
indications from the Michigan study were that when the
assignment of donors was made nonselective as alternate
cases or was completely randomized, graft survival in the
control and treated groups was equalized.
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Graft survival in months for three different dosage regimens: Selected
(
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o
o), and randomized (*
A
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kidneys (100 mg/K) now tend to minimize the hazard of
using perfusion to preserve pretreated kidneys.
The dosage of cyclophosphamide and methylprednisolone
in these clinical studies has varied from 40 to 80 mg/ K. The
higher dose of cyclophosphamide has not produced any
appreciable loss of renal function, and the preferred dose
has become 5.0 gm or 70 mg/ K for an adult donor. In fact,
pretreated kidneys provide the recipients with a lower mean
creatinine level during the first four weeks postoperatively.
The optimal dosage of methylprednisolone is more equivocal. Although dosages have been increased to as high as 70
mg/K, a fall in graft survival of pretreated kidneys was
associated with dosages between 40 and 70 mg/K in both
this study and in the Michigan study." This may or may not
be a significant variable. Observations from the use of three
consecutive daily doses of methylprednisolone system icaliy
in the dog after transplantation indicate that 70 m g / K will
produce a consistent loss of function and definite glomerular
and tubular lesions.'" Therefore, 30 to 50 mg/K of methylprednisolone would seem to be the appropriate range.

The general scientific criticism of donor pretreatment as an
applied clinical method for augmenting kidney graft survival
is that, like other immunological methods which work well
in small inbred animals, it has notbeen shown to be effective
in an outbred species. However, Woods has shown moderate prolongation of mongrel canine kidney allografts by
pretreatment of the donors with procarbazine." We have
recently shown in dogs that cyclophosphamide and methylprednisolone acting over 18 to 24 hours in the donor can
produce very significant extension of graft survival. It remains to be determined whether a protocol with a longer
donor pretreatment interval such as this is necessary for
human cadaver kidney doners.

Conclusions
1) The use of continuous perfusion preservation for human
kidneys does not interdict the use of cyclophosphamide
for donor pretreatment.

The third variable in these clinical trials was the randomizing of kidneys between pretreated and control groups. In
Guttmann's series, the pretreated donors came from the
transplant center hospital, while the donors used for controls
were harvested at other hospitals. In both groups, ice storage
was the method of preservation.' The grafts were followed
for three and a half years, and survival between pretreated
and nontreated was 81% versus 60%. Similady, in the study
by Zincke at the Mayo Clinic, pretreated kidneys were
harvested locally, while kidneys harvested by other teams
and transported long distances were used as the control

2) Dosages of upto 70 mg/K of cyclophosphamide may be
used without an apparent increase in acute tubular
necrosis or significant early loss of renal function.
3) Further truly randomized clinical trials will be necessary
to establish donor pretreatment as a means of reducing
rejection and extending human kidney graft survival.
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